AMZN, CAH, LRN and EAT stand out with strong interest coverage ratios to help weather 2026's shifting market tides.

OKLO's one-step NRC licensing strategy could speed up deployment by reusing approvals across future sites.

PH is seeing accelerating aerospace momentum, with strong OEM and aftermarket demand supporting upbeat fiscal 2026 growth guidance.

POWL is benefiting from strong utility demand, a growing backlog and strategic investments, supported by solid liquidity and a debt-free balance sheet.

Tomorrow marks Warren Buffett's final day as CEO of Berkshire Hathaway (NYSE:BRK-A)(NYSE:BRK-B), ending a tenure spanning six decades that turned a struggling textile company into a $1 trillion conglomerate.

LOS ANGELES, Dec. 30, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Six Flags Entertainment Corporation, (“Six Flags” or the "Company") (NYSE: FUN) investors of a class action on behalf of investors that bought securities in connection with the July 1, 2024 merger of legacy Six Flags Entertainment Corporation (“Legacy Six Flags”) with Cedar Fair, L.P. (“Cedar Fair”), and their subsidiaries and affiliates. Six Flags investors have until January 5, 2026 to file a lead plaintiff motion.

RADNOR, Pa., Dec. 30, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) (“uniQure”).

Palantir (PLTR) is rated a strong buy, driven by operational leverage and rapid industrialization of its AIPlatform in the U.S. commercial sector. PLTR's Bootcamp sales model has created a high-velocity deal-closing flywheel, with U.S. commercial revenue up 121% Y/Y and TCV up 342% Y/Y in Q3-FY2025. Despite a forward P/E >250x and governance risks, PLTR's 114% Rule of 40 score, high margins, and strong cash position support aggressive long-term accumulation.

Stride, Inc. LRN has been prioritizing margin expansion and operational discipline amid in-house technical issues and a flat year-over-year revenue per enrollment. This education service provider exited the first quarter of fiscal 2026 with an adjusted operating margin of 13.1%, up 250 basis points (bps) year over year, and an adjusted EBITDA margin of 17.5%, up 230 bps.

CNQ's dividend durability, low-cost assets and capital discipline make it attractive for income investors heading into 2026.

The Artificial Intelligence arms race is going to enter a decisive phase after years of heavy investment in chips, data centers and foundational models. The focus is now shifting toward scale, monetization and competitive advantage.

After soaring in 2023 and 2024, shares of Tesla (NASDAQ:TSLA) were battered throughout the first half of 2025.

LOS ANGELES, Dec. 30, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Perrigo Company plc, (“Perrigo” or the "Company") (NYSE: PRGO) investors of a class action on behalf of investors that bought securities between February 27, 2023 and November 4, 2025, inclusive (the “Class Period”). Perrigo investors have until January 16, 2026 to file a lead plaintiff motion.

Shares of Rivian Automotive (NASDAQ:RIVN) lost 9.06% over the past five trading sessions after gaining 17.25%% the five prior.

LOS ANGELES, Dec. 30, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises CarMax, Inc., (“CarMax” or the "Company") (NYSE: KMX) investors of a class action on behalf of investors that bought securities between March 5, 2024 and October 8, 2025, inclusive (the “Class Period”). CarMax, Inc. investors have until January 2, 2026 to file a lead plaintiff motion.

UNFI, INGR and BYND stand out as food stocks using cost control, pricing discipline and focused innovation to enter the new year strong.

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Centrus Energy begins industrial-scale centrifuge manufacturing in Ohio, a key step toward restoring U.S.-owned uranium enrichment after a decade-long gap.

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.